Jessica E Ericson1, David A Kaufman2, Stephen D Kicklighter3, Jatinder Bhatia4, Daniela Testoni5, Jamie Gao6, P Brian Smith7, Kristi O Prather6, Daniel K Benjamin7. 1. Department of Pediatrics, Penn State College of Medicine, Hershey, Pennsylvania. 2. Department of Pediatrics, University of Virginia, Charlottesville. 3. Wake Medical Center, Raleigh, North Carolina. 4. Department of Pediatrics, Georgia Regents University, Augusta. 5. Escola Paulista de Medicina, Universidade Federal de São Paulo, Brazil. 6. Duke Clinical Research Institute. 7. Duke Clinical Research Institute Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.
Abstract
BACKGROUND: Invasive candidiasis (IC) is an important cause of sepsis in premature infants and is associated with a high risk of death and neurodevelopmental impairment. Prevention of IC has become a major focus in very low birth weight infants, with fluconazole increasingly used as prophylaxis. METHODS: We identified all randomized, placebo-controlled trials evaluating fluconazole prophylaxis in premature infants conducted in the United States. We obtained patient-level data from the study investigators and performed an aggregated analysis. The occurrence of each endpoint in infants who received prophylaxis with fluconazole vs placebo was compared. Endpoints evaluated were IC or death, IC, death, Candida colonization, and fluconazole resistance among tested isolates. Safety endpoints evaluated included clinical and laboratory parameters. RESULTS: Fluconazole prophylaxis reduced the odds of IC or death, IC, and Candida colonization during the drug exposure period compared with infants given placebo: odds ratios of 0.48 (95% confidence interval [CI], .30-.78), 0.20 (95% CI, .08-.51), and 0.28 (95% CI, .18-.41), respectively. The incidence of clinical and laboratory adverse events was similar for infants who received fluconazole compared with placebo. There was no statistically significant difference in the proportion of tested isolates that were resistant to fluconazole between the fluconazole and placebo groups. CONCLUSIONS: Fluconazole prophylaxis is effective and safe in reducing IC and Candida colonization in premature infants, and has no impact on resistance.
BACKGROUND: Invasive candidiasis (IC) is an important cause of sepsis in premature infants and is associated with a high risk of death and neurodevelopmental impairment. Prevention of IC has become a major focus in very low birth weight infants, with fluconazole increasingly used as prophylaxis. METHODS: We identified all randomized, placebo-controlled trials evaluating fluconazole prophylaxis in premature infants conducted in the United States. We obtained patient-level data from the study investigators and performed an aggregated analysis. The occurrence of each endpoint in infants who received prophylaxis with fluconazole vs placebo was compared. Endpoints evaluated were IC or death, IC, death, Candida colonization, and fluconazole resistance among tested isolates. Safety endpoints evaluated included clinical and laboratory parameters. RESULTS: Fluconazole prophylaxis reduced the odds of IC or death, IC, and Candida colonization during the drug exposure period compared with infants given placebo: odds ratios of 0.48 (95% confidence interval [CI], .30-.78), 0.20 (95% CI, .08-.51), and 0.28 (95% CI, .18-.41), respectively. The incidence of clinical and laboratory adverse events was similar for infants who received fluconazole compared with placebo. There was no statistically significant difference in the proportion of tested isolates that were resistant to fluconazole between the fluconazole and placebo groups. CONCLUSIONS: Fluconazole prophylaxis is effective and safe in reducing IC and Candida colonization in premature infants, and has no impact on resistance.
Authors: Daniel K Benjamin; Barbara J Stoll; Avory A Fanaroff; Scott A McDonald; William Oh; Rosemary D Higgins; Shahnaz Duara; Kenneth Poole; Abbot Laptook; Ronald Goldberg Journal: Pediatrics Date: 2006-01 Impact factor: 7.124
Authors: C Michael Cotten; Scott McDonald; Barbara Stoll; Ronald N Goldberg; Kenneth Poole; Daniel K Benjamin Journal: Pediatrics Date: 2006-08 Impact factor: 7.124
Authors: L Saiman; E Ludington; J D Dawson; J E Patterson; S Rangel-Frausto; R T Wiblin; H M Blumberg; M Pfaller; M Rinaldi; J E Edwards; R P Wenzel; W Jarvis Journal: Pediatr Infect Dis J Date: 2001-12 Impact factor: 2.129
Authors: Mariam Aziz; Aloka L Patel; Jennifer Losavio; Anjali Iyengar; Michael Berven; Nathan Schloemer; Andrew Jakubowicz; Tina Mathai; James B McAuley Journal: Pediatr Infect Dis J Date: 2010-04 Impact factor: 2.129
Authors: Ira Adams-Chapman; Carla M Bann; Abhik Das; Ronald N Goldberg; Barbara J Stoll; Michele C Walsh; Pablo J Sánchez; Rosemary D Higgins; Seetha Shankaran; Kristi L Watterberg; Shahnaz Duara; Nancy A Miller; Roy J Heyne; Myriam Peralta-Carcelen; Ricki F Goldstein; Jean J Steichen; Charles R Bauer; Susan R Hintz; Patricia W Evans; Michael J Acarregui; Gary J Myers; Betty R Vohr; Deanne E Wilson-Costello; Athina Pappas; Yvonne E Vaucher; Richard A Ehrenkranz; Elisabeth C McGowan; Robert G Dillard; Janell Fuller; Daniel K Benjamin Journal: J Pediatr Date: 2013-05-30 Impact factor: 4.406
Authors: Daniel K Benjamin; Mark L Hudak; Shahnaz Duara; David A Randolph; Margarita Bidegain; Gratias T Mundakel; Girija Natarajan; David J Burchfield; Robert D White; Karen E Shattuck; Natalie Neu; Catherine M Bendel; M Roger Kim; Neil N Finer; Dan L Stewart; Antonio C Arrieta; Kelly C Wade; David A Kaufman; Paolo Manzoni; Kristi O Prather; Daniela Testoni; Katherine Y Berezny; P Brian Smith Journal: JAMA Date: 2014-05-07 Impact factor: 157.335
Authors: Sofia Aliaga; Reese H Clark; Matthew Laughon; Thomas J Walsh; William W Hope; Daniel K Benjamin; David Kaufman; Antonio Arrieta; Daniel K Benjamin; P Brian Smith Journal: Pediatrics Date: 2014-01-20 Impact factor: 9.703
Authors: S S Haslund-Krog; I M Jorgensen; T B Henriksen; K Dalhoff; N M Debes; J van den Anker; H Holst Journal: Contemp Clin Trials Commun Date: 2021-06-21